Novartis' Entresto gains steam with cardiologists despite stinging heart failure trial flop

Novartis' blockbuster Entresto missed a big opportunity last year with a failed late-stage trial in certain heart failure patients without a current approved treatment. Despite that loss, and a slow start to market, analysts say Entresto is picking up steam with cardiologists—and it could translate into a major sales boost.